APA (7th ed.) Citation

C, R., B, C., C, H., TJ, M., C, F., O, C., . . . JP, J. (2011). Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet, 378(9806), 1858. https://doi.org/10.1016/s0140-6736(11)61040-4

Chicago Style (17th ed.) Citation

C, Récher, et al. "Intensified Chemotherapy with ACVBP Plus Rituximab Versus Standard CHOP Plus Rituximab for the Treatment of Diffuse Large B-cell Lymphoma (LNH03-2B): An Open-label Randomised Phase 3 Trial." Lancet 378, no. 9806 (2011): 1858. https://doi.org/10.1016/s0140-6736(11)61040-4.

MLA (9th ed.) Citation

C, Récher, et al. "Intensified Chemotherapy with ACVBP Plus Rituximab Versus Standard CHOP Plus Rituximab for the Treatment of Diffuse Large B-cell Lymphoma (LNH03-2B): An Open-label Randomised Phase 3 Trial." Lancet, vol. 378, no. 9806, 2011, p. 1858, https://doi.org/10.1016/s0140-6736(11)61040-4.